TPST
HEALTHCARETempest Therapeutics Inc
AI Insight
What's Moving TPST Today?
No stock-specific AI insight has been generated for TPST yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.22$12.23
$1.26
Fundamentals
Market Cap$18M
P/E Ratio—
EPS$-5.70
Dividend Yield—
Dividend / Share—
ROE-721.0%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding14.8M
TPST News
22 articles- [Form 3] Tempest Therapeutics, Inc. Initial Statement of Beneficial OwnershipStock Titan·Jun 18, 2026
- Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsYahoo Finance·Jun 4, 2026
- Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross ProceedsYahoo Finance·May 29, 2026
- Tempest Therapeutics receives Nasdaq notice for listing deficienciesInvesting.com·May 23, 2026
- Tempest Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 14, 2026
- Tempest Presents Clinical Update at ISCT 2026 Annual MeetingYahoo Finance·May 6, 2026
- Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingGlobeNewswire Inc.·Apr 29, 2026
- Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TYahoo Finance·Apr 22, 2026
- Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsYahoo Finance·Apr 14, 2026
- New Strong Buy Stocks for April 10thYahoo Finance·Apr 10, 2026
- Tempest Reports Year End 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 30, 2026
- Tempest Therapeutics Announces Up To $6 Million Private PlacementYahoo Finance·Mar 23, 2026
- Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026Yahoo Finance·Mar 11, 2026
- Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026Yahoo Finance·Feb 25, 2026
- Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T AssetsYahoo Finance·Feb 11, 2026
- Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T AssetsYahoo Finance·Feb 4, 2026
- Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to StockholdersYahoo Finance·Jan 20, 2026
- Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq RulesYahoo Finance·Nov 26, 2025
- Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq RulesYahoo Finance·Nov 25, 2025
- Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027Yahoo Finance·Nov 19, 2025
- Tempest Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 5, 2025
- Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical OfficerYahoo Finance·Aug 13, 2025
All 22 articles loaded
Price Data
Open$1.26
Previous Close$1.26
Day High$1.30
Day Low$1.24
52 Week High$12.23
52 Week Low$1.22
52-Week Range
$1.22$12.23
$1.26
Fundamentals
Market Cap$18M
P/E Ratio—
EPS$-5.70
Dividend Yield—
Dividend / Share—
ROE-721.0%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding14.8M
About Tempest Therapeutics Inc
Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—